Safer and More Convenient Modern Curative Radiotherapy for Patients With Early Prostate Cancer
Anticancer Research · 2024
DOI: 10.21873/anticanres.16796 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Anticancer Research, 2024. Verfasst von Petri Reinikainen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Health Technology and TAUH Cancer Center, Tampere University Hospital, Tampere, Finland; petri.reinikainen@tuni.fi. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Radiosurgery, Gastrointestinal Diseases.
Abstract (Originalsprache)
BACKGROUND/AIM: New fractionation schedules with modern tools are a very rapidly developing area in curative radiotherapy (RT) for early prostate cancer (PC). To apply these techniques in everyday clinical practice, we planned this phase II trial with different fractionation schedules and followed up patients using careful health-related quality of life (QoL) questionnaires for three years. PATIENTS AND METHODS: Seventy-three PC patients with one or two intermediate PC risk factors according to the National Comprehensive Cancer Network criteria were recruited. Forty-two patients were treated with 78/2 Gy (conventional fractionation, CF) or 60/3 Gy (moderately hypofractionation RT, MHF), and 31 patients were treated with 36.25/7.25 Gy (stereotactic body RT, SBRT). Their PSA levels were measured, and QoL data were assessed for genitourinary (GU), gastrointestinal (GI), and sexual well-being between the baseline and three years after treatment. A Rectafix™ (RF) fixation device was used in 30 patients in the CF/MHF group. RESULTS: Three years after radiotherapy (RT), there were no differences between the groups regarding GU, GI, sexual well-being, PSA response, or clinical outcomes. On QoL questionnaires, men in the SBRT group were more satisfied with their QoL at the end of RT. Urinary symptoms (p=0.004) and urinary incontinence were more common in the CF/MHF group (p=0.016) three months after RT. The use of RF reduced GI toxicity, especially urgency (p=0.002), at three years after RT. CONCLUSION: Modern, short, five-fraction stereotactic radiotherapy as a local curative treatment for PC is well tolerated and safe. Our novel results showing a decrease in GI toxicity using Rectafix™ fixation should be confirmed in future randomized trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine and Health Technology and TAUH Cancer Center, Tampere University Hospital, Tampere, Finland; petri.reinikainen@tuni.fi.
- Faculty of Information Technology and Communication Sciences, Tampere, Finland.
- Research, Development and Innovation Center, Tampere University Hospital, and Health Sciences, Faculty of Social Sciences, Tampere University, Tampere, Finland.
- Faculty of Medicine and Health Technology and TAUH Cancer Center, Tampere University Hospital, Tampere, Finland.
Zitieren
APA
Reinikainen, P., Lehtinen, I., Luukkaala, T., & Kellokumpu-Lehtinen, P. L. (2024). Safer and More Convenient Modern Curative Radiotherapy for Patients With Early Prostate Cancer. Anticancer Research. https://doi.org/10.21873/anticanres.16796
Vancouver
Reinikainen P, Lehtinen I, Luukkaala T, Kellokumpu-Lehtinen PL. Safer and More Convenient Modern Curative Radiotherapy for Patients With Early Prostate Cancer. Anticancer Research. 2024. doi:10.21873/anticanres.16796
BibTeX
@article{Reinikainen2024,
author = {Reinikainen, Petri and Lehtinen, Ilari and Luukkaala, Tiina and Kellokumpu-Lehtinen, Pirkko-Liisa},
title = {Safer and More Convenient Modern Curative Radiotherapy for Patients With Early Prostate Cancer},
journal = {Anticancer Research},
year = {2024},
doi = {10.21873/anticanres.16796}
}
EUVIMED